Explore the May 2026 lupus landscape, featuring the newly approved Saphnelo Pen (anifrolumab SC), Gazyva (obinutuzumab) success, and the latest in CAR-T cell therapy for SLE.
An audit of rising antinuclear antibody (ANA) prevalence, NIH research obligations, and the institutional silos leaving 50 million Americans underserved.
